Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients. Following the FDA approval of ranibizumab-hkdz (Ranluspec; ...

Findings from an 856-patient analysis suggest that evaluating GA topography beyond foveal involvement may better capture patient-reported functional impairment. Anegondi and colleagues analyzed ...

Study shows RB1-positive infants diagnosed before 9 months face higher fellow-eye retinoblastoma risk, guiding smarter surveillance and de-escalation. Age at diagnosis may change genetic risk ...

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). NovaBridge Biosciences ...

Neovascular AMD and DME therapies: 5 quotes from retina specialists ...

The value of attending industry meetings at the beginning of a career in ophthalmology. Attending the American Academy of Ophthalmology (AAO) Annual Meeting for the first time can feel overwhelming.

A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition. A panelist discusses ...

At the 2025 EURETINA Congress, Prof Korobelnik delivered the Gisbert Richard Lecture, focusing on removal of intra-ocular foreign bodies and mitigating ocular trauma. Jean-Francois Korobelnik, MD, ...

María Berrocal, MD, titled her Kreissig Award Lecture "Throwing away wisdom: How we abandon what works." María Berrocal, from Drs. Berrocal and Associates in San Juan, Puerto Rico, delivered the ...

During her Ophthalmologica Lecture at the 2025 EURETINA Congress, Prof Cicinelli explained why it's time for a different approach to white spot syndromes. During her Ophthalmologica Lecture at the ...

Research reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support. Sally S. Ong, MD, presented ...

jCyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa. jCyte recently announced the dosing of the first patients enrolled in the ...